Literature DB >> 32068457

Juvenile OLFM4-null mice are protected from sepsis.

Julie E Stark1, Amy M Opoka1, Jaya Mallela1, Prasad Devarajan2, Qing Ma2, Nick C Levinsky3, Keith F Stringer4, Hector R Wong1, Matthew N Alder1.   

Abstract

Pediatric sepsis is a leading cause of morbidity and mortality in children. One of the most common and devastating morbidities is sepsis-related acute kidney injury (AKI). AKI was traditionally thought to be related to low perfusion and acute tubular necrosis. However, little acute tubular necrosis can be found following septic AKI, and little is known about the mechanism of septic AKI. Olfactomedin-4 (OLFM4) is a secreted glycoprotein that marks a subset of neutrophils. Increased expression of OLFM4 in the blood is associated with worse outcomes in sepsis. Here, we investigated a pediatric model of murine sepsis using murine pups to investigate the mechanisms of OLFM4 in sepsis. When sepsis was induced in murine pups, survival was significantly increased in OLFM4-null pups. Immunohistochemistry at 24 h after the induction of sepsis demonstrated increased expression of OLFM4 in the kidney, which was localized to the loop of Henle. Renal cell apoptosis and plasma creatinine were significantly increased in wild-type versus OLFM4-null pups. Finally, bone marrow transplant suggested that increased OLFM4 in the kidney reflects local production rather than filtered from the plasma. These results demonstrate renal expression of OLFM4 for the first time and suggest that a kidney-specific mechanism may contribute to survival differences in OLFM4-null animals.

Entities:  

Keywords:  infection; kidney injury; neutrophil; olfactomedin-4; pediatric

Mesh:

Substances:

Year:  2020        PMID: 32068457      PMCID: PMC7099509          DOI: 10.1152/ajprenal.00443.2019

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  34 in total

Review 1.  The pathophysiology and treatment of sepsis.

Authors:  Richard S Hotchkiss; Irene E Karl
Journal:  N Engl J Med       Date:  2003-01-09       Impact factor: 91.245

Review 2.  Stem cell marker olfactomedin 4: critical appraisal of its characteristics and role in tumorigenesis.

Authors:  Phulwinder K Grover; Jennifer E Hardingham; Adrian G Cummins
Journal:  Cancer Metastasis Rev       Date:  2010-12       Impact factor: 9.264

3.  Olfactomedin-4 Is a Candidate Marker for a Pathogenic Neutrophil Subset in Septic Shock.

Authors:  Matthew N Alder; Amy M Opoka; Patrick Lahni; David A Hildeman; Hector R Wong
Journal:  Crit Care Med       Date:  2017-04       Impact factor: 7.598

Review 4.  Histopathology of Septic Acute Kidney Injury: A Systematic Review of Experimental Data.

Authors:  Junko Kosaka; Yugeesh R Lankadeva; Clive N May; Rinaldo Bellomo
Journal:  Crit Care Med       Date:  2016-09       Impact factor: 7.598

5.  Why have clinical trials in sepsis failed?

Authors:  John C Marshall
Journal:  Trends Mol Med       Date:  2014-02-24       Impact factor: 11.951

6.  Global epidemiology of pediatric severe sepsis: the sepsis prevalence, outcomes, and therapies study.

Authors:  Scott L Weiss; Julie C Fitzgerald; John Pappachan; Derek Wheeler; Juan C Jaramillo-Bustamante; Asma Salloo; Sunit C Singhi; Simon Erickson; Jason A Roy; Jenny L Bush; Vinay M Nadkarni; Neal J Thomas
Journal:  Am J Respir Crit Care Med       Date:  2015-05-15       Impact factor: 21.405

7.  Olfactomedin 4 inhibits cathepsin C-mediated protease activities, thereby modulating neutrophil killing of Staphylococcus aureus and Escherichia coli in mice.

Authors:  Wenli Liu; Ming Yan; Yueqin Liu; Kenneth R McLeish; William G Coleman; Griffin P Rodgers
Journal:  J Immunol       Date:  2012-07-27       Impact factor: 5.422

8.  Pediatric severe sepsis: current trends and outcomes from the Pediatric Health Information Systems database.

Authors:  Amanda Ruth; Courtney E McCracken; James D Fortenberry; Matthew Hall; Harold K Simon; Kiran B Hebbar
Journal:  Pediatr Crit Care Med       Date:  2014-11       Impact factor: 3.624

9.  OLFM4 Enhances STAT3 Activation and Promotes Tumor Progression by Inhibiting GRIM19 Expression in Human Hepatocellular Carcinoma.

Authors:  Yosuke Ashizawa; Satoshi Kuboki; Hiroyuki Nojima; Hideyuki Yoshitomi; Katsunori Furukawa; Tsukasa Takayashiki; Shigetsugu Takano; Masaru Miyazaki; Masayuki Ohtsuka
Journal:  Hepatol Commun       Date:  2019-05-02

Review 10.  The changing immune system in sepsis: is individualized immuno-modulatory therapy the answer?

Authors:  Jonathan S Boomer; Jonathan M Green; Richard S Hotchkiss
Journal:  Virulence       Date:  2013-09-25       Impact factor: 5.882

View more
  5 in total

Review 1.  Olfactomedin 4 Is a Biomarker for the Severity of Infectious Diseases.

Authors:  Wenli Liu; Griffin P Rodgers
Journal:  Open Forum Infect Dis       Date:  2022-02-08       Impact factor: 3.835

2.  Bioinformatic analysis identifies potential biomarkers and therapeutic targets of septic-shock-associated acute kidney injury.

Authors:  Yun Tang; Xiaobo Yang; Huaqing Shu; Yuan Yu; Shangwen Pan; Jiqian Xu; You Shang
Journal:  Hereditas       Date:  2021-04-16       Impact factor: 3.271

3.  Increased expression of OLFM4 and lysozyme during necrotizing enterocolitis in neonates: an observational research study.

Authors:  Sonja Diez; Marcus Renner; Veronika Bahlinger; Arndt Hartmann; Manuel Besendörfer; Hanna Müller
Journal:  BMC Pediatr       Date:  2022-04-11       Impact factor: 2.125

4.  Olfactomedin 4 as a novel loop of Henle-specific acute kidney injury biomarker.

Authors:  Denise C Hasson; Kelli Krallman; Katherine VanDenHeuvel; Shina Menon; Giovanna Piraino; Prasad Devarajan; Stuart L Goldstein; Matthew N Alder
Journal:  Physiol Rep       Date:  2022-09

5.  Identification of alternative protein targets of glutamate-ureido-lysine associated with PSMA tracer uptake in prostate cancer cells.

Authors:  Martin K Bakht; John J Hayward; Farsheed Shahbazi-Raz; Magdalena Skubal; Ryo Tamura; Keith F Stringer; Daniel Meister; Varadha Balaji Venkadakrishnan; Hui Xue; Adam Pillon; Mathew Stover; Adam Tronchin; Bre-Anne Fifield; Lavleen Mader; Sheng-Yu Ku; Gi Jeong Cheon; Keon Wook Kang; Yuzhuo Wang; Xuesen Dong; Himisha Beltran; Jan Grimm; Lisa A Porter; John F Trant
Journal:  Proc Natl Acad Sci U S A       Date:  2022-01-25       Impact factor: 12.779

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.